Enveric Biosciences, Inc.

ENVB Nasdaq SEC CIK 890821
Follow Enveric Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$2.5M −36.1% vs same quarter last year
EPS, diluted −$0.57
Operating cash flow −$2.7M −27.8% vs same quarter last year
Operating income −$2.6M −36.8% vs same quarter last year
Net income by quarter
$16M
−$2.2M
−$2.5M
−$1.9M
$18.7M
−$1.6M
−$3M
−$2.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$50M−$25M$0$25M$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25--
FY24--
FY23--
FY22-−$18.5M
FY21-−$49M
FY20-−$6.9M
FY19$39.9M−$2.4M
FY18$43M−$16.9M
FY17$48.6M−$9.1M
FY16$36.1M−$2.8M
FY15$20.3M−$814.1K
FY14$6.1M$414.6K
FY13-−$161
FY12-−$24.6K
FY11-−$33.4K
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−40%−20%0%20%40%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY22---
FY21---
FY20---
FY1920.4%−5.8%−6%
FY1820.9%−16.6%−39.3%
FY1721.1%−22.4%−18.7%
FY1619.2%−14.9%−7.7%
FY1533.9%−3.9%−4%
FY1414.8%10.2%6.7%
FY13---
FY12---
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23−$14.1M
FY22−$17.7M
FY21−$11.6M
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Enveric Biosciences
  • Healthcare median
−100%−75%−50%−25%0%25%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearEnveric BiosciencesHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19−6%−46.2%
FY18−39.3%−49.6%
FY17−18.7%−45.9%
FY16−7.7%−36%
FY15−4%−37.8%
FY146.7%−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%